Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
EdiGene Inc. logo — Edit the Code of Life, Creating Transformative Solutions for...

EdiGene Inc.

Edit the Code of Life, Creating Transformative Solutions for Serious Diseases.

Founded 2015 China Beijing, China 46 employees Series B Total: $180.04M Biotechnology, Health Care

General Information

Company Name EdiGene Inc.
Founded Year 2015
Location China Beijing, China +1
Employees 46
Industries Biotechnology, Health Care
Funding Stage Series B
Social

Get notified when EdiGene Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About EdiGene Inc.

EdiGene Inc., founded in 2015, is a clinical-stage biotech company based in China, dedicated to innovating through gene-editing technologies. Their motto, "Edit the Code of Life, Creating Transformative Solutions for Serious Diseases," captures the essence of their mission in the Biotechnology and Health Care sectors.

EdiGene specializes in developing groundbreaking genetic medicines for conditions with significant unmet medical needs. The company leverages its proprietary technologies across therapeutic platforms, including LEAPER-based in vivo RNA base editing, and ex vivo gene-editing hematopoietic stem cells and ex vivo gene-editing T cells for allogeneic CAR-T applications.

The company's latest financial milestone was a $62.00M Series B investment on 01 April 2021. Key investors like Lilly Asia Ventures, IDG Capital, and 3H Health Investment highlight strong backing from prominent players in the venture capital community.

Taxonomy: Gene Editing, Genetic Medicines, RNA Base Editing, Hematopoietic Stem Cell Editing, CAR-T Therapy, Genome Editing Technology, Molecular-Level Treatment, Gene Knockout, Gene Knock-in, Targeted Mutations, High Throughput Screening, Bioinformatics, Ex Vivo Gene Editing, In Vivo Gene Editing, Therapeutic Platforms

Services & Products

Gene Editing Technologies
RNA Editing Solutions
Cell and Gene Therapies
Therapeutic Development Platforms
High-Throughput Genomic Screening

Target Customers

Healthcare Providers Biotech Researchers Pharmaceutical Companies Medical Practitioners Patients with Genetic Disorders

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 10
Investor Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Apr 2021
Series B •••••• 8
Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Oct 2020
Early VC •••••• 2
Investor Investor
01 Sep 2019
Early VC •••••• 3
Investor Investor
•••• •••• 		01 Feb 2019
Early VC •••••• - 01 Aug 2018

View All 6 Funding Rounds

EdiGene Inc. Alternatives & Competitors

EdiGene Inc. vs
Precision BioSciences, Inc.
Precision BioSciences, Inc. United States

Dedicated to Improving Life.

Post Ipo Equity
98 employees
Biotechnology, Health Care
Compare EdiGene Inc. vs Precision BioSciences, Inc.
EdiGene Inc. vs
Spotlight Therapeutics
Spotlight Therapeutics United States

Biotechnology company that develops biologics targeted to specific cell populations in gene editing

Series B
22 employees
Biotechnology, Health Care
Compare EdiGene Inc. vs Spotlight Therapeutics
EdiGene Inc. vs
Mammoth Biosciences
Mammoth Biosciences United States

Improving lives by reading and writing the code of life.

Unknown
164 employees
Biotechnology, Health Care
Compare EdiGene Inc. vs Mammoth Biosciences

FAQ About EdiGene Inc.

Edit the Code of Life, Creating Transformative Solutions for Serious Diseases.
EdiGene Inc. was founded in 2015.
EdiGene Inc. is headquartered in Beijing, China.
EdiGene Inc. operates in the following industries: Biotechnology, Health Care.
EdiGene Inc. has approximately 46 employees.
EdiGene Inc. has completed 6 funding rounds, raising a total of $180.04M. The latest funding stage is Series B.
EdiGene Inc. offers: Gene Editing Technologies, RNA Editing Solutions, Cell and Gene Therapies, Therapeutic Development Platforms, High-Throughput Genomic Screening.
Top alternatives and competitors to EdiGene Inc. include Precision BioSciences, Inc., Spotlight Therapeutics, Mammoth Biosciences, AccurEdit Therapeutics, CorrectSequence Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
EdiGene Inc. and Precision BioSciences, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors EdiGene Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy